Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06063317 · ClinicalTrials.gov registry record · Phase 1
A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)
A Phase 1 study, sponsored by Imugene Limited.
- Terminated
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT06063317 is a Phase 1 study that was terminated before completion, run by Imugene Limited. The registered enrollment target is 25 participants.
The verdict
NCT06063317, a Phase 1 study, was terminated before completion, sponsored by Imugene Limited.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is an open-label, dose escalation and dose expansion, multi-center phase I study evaluating the safety and tolerability of CF33-CD19 administered intravenously (IV) or intratumorally (IT) in combination with blinatumomab and with or without hydroxyurea in adults with advanced or metastatic solid tumors.
Interventions
- DRUG Blinatumomab
- BIOLOGICAL CF33-CD19 IT Monotherapy
- BIOLOGICAL CF33-CD19 IV Monotherapy
- BIOLOGICAL CF33-CD19 IT Combination
- BIOLOGICAL CF33-CD19 IV Combination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2023-10-02 |
| Est. Completion | 2026-02-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06063317
The ClinicalTrials.gov registry entry for NCT06063317 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Imugene Limited, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Blinatumomab is the first listed.
NCT06063317 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06063317 about?
NCT06063317 is a clinical study titled "A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)". This is an open-label, dose escalation and dose expansion, multi-center phase I study evaluating the safety and tolerability of CF33-CD19 administered intravenously (IV) or intratumorally (IT) in combination with blinatumomab and with or without hydroxyurea in adults with advanced or metastatic soli...
What is the current status of trial NCT06063317?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2023-10-02. Estimated completion is 2026-02-02.
What interventions are being tested in trial NCT06063317?
The interventions under investigation include: Blinatumomab (DRUG), CF33-CD19 IT Monotherapy (BIOLOGICAL), CF33-CD19 IV Monotherapy (BIOLOGICAL), CF33-CD19 IT Combination (BIOLOGICAL), CF33-CD19 IV Combination (BIOLOGICAL).
Who is sponsoring clinical trial NCT06063317?
This trial is sponsored by Imugene Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.